ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA
January 30, 2024 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
January 29, 2024 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
ProSomnus Comments on Insurance Coverage Policy Update for Obstructive and Central Sleep Apnea
January 08, 2024 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, welcomes the adoption of...
Data Published by Cureus Journal of Medical Science Shows Successful Treatment of Obstructive Sleep Apnea with ProSomnus Precision Oral Appliance Devices
December 19, 2023 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, today announced the publication of a...
ProSomnus, the Leading Non-CPAP Obstructive Sleep Apnea Therapy, Reports Record Third Quarter 2023 Financial Results
November 09, 2023 16:17 ET
|
ProSomnus Sleep Technologies, Inc.
ProSomnus, the Leading Non-CPAP Obstructive Sleep Apnea Therapy, Reports Record Third Quarter 2023 Financial Results
ProSomnus Announces Third Quarter 2023 Investor Call and Business Update
October 31, 2023 16:05 ET
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), will report its third quarter...
ProSomnus Announces Participation in the 2023 Roth Capital Healthcare Opportunities Conference
October 03, 2023 16:05 ET
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), today announces...
ProSomnus Raises $10 Million To Fuel Growth and Optimize Operations
September 21, 2023 08:30 ET
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), today announced...
ProSomnus Precision Obstructive Sleep Apnea Devices to be Featured in Scientific Abstracts and Podium Presentations at Upcoming Medical Conferences
September 14, 2023 08:30 ET
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), today announced that their...
Updated Clinical Trial Data Indicates Precision Oral Appliance Therapy with ProSomnus Devices is Non-Inferior to CPAP Therapy for the Treatment of Moderate to Severe Obstructive Sleep Apnea
August 23, 2023 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
Precision oral appliance therapy effective among 90% of moderate and 85% of severe OSA patients In an Intent-to-Treat analysis, precision OAT demonstrated twice the mean disease alleviation as...